International Journal of Hematology

, Volume 89, Issue 5, pp 664–672

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia

  • Dong-Wook Kim
  • Yeow-Tee Goh
  • Hui-Hua Hsiao
  • Priscilla B. Caguioa
  • Dongho Kim
  • Wan-Seok Kim
  • Tapan Saikia
  • Shruti Agrawal
  • Amit Roy
  • David Dai
  • M. Brigid Bradley-Garelik
  • Jaydip Mukhopadhyay
  • Saengsuree Jootar
Original Article

DOI: 10.1007/s12185-009-0326-1

Cite this article as:
Kim, DW., Goh, YT., Hsiao, HH. et al. Int J Hematol (2009) 89: 664. doi:10.1007/s12185-009-0326-1

Abstract

Resistance and intolerance to imatinib are of particular clinical relevance to Asian patients because of their lower body surface area. Dasatinib is 325-fold more potent than imatinib in inhibiting BCR-ABL in vitro and is indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib. Data from a series of phase I/II research trials were analyzed to compare the efficacy, safety and pharmacokinetic profile of dasatinib 70 mg twice daily in Asian and non-Asian patients. Results from 55 Asian and 615 non-Asian patients demonstrated that the efficacy and safety of dasatinib was comparable. Dasatinib was well tolerated, with no observed toxicities exclusive to Asian patients. A higher incidence of adverse events and lower rate of response observed among Asian patients with myeloid blast phase CML reflected the aggressive nature of the disease. Analyses of noncompartmental pharmacokinetics (5 Asian and 49 non-Asian patients) and population pharmacokinetics (17 Asian and 382 non-Asian patients) were also comparable. The efficacy, safety and pharmacokinetic profile of dasatinib 70 mg twice daily is similar in Asian and non-Asian patients with CML. Dasatinib is therefore an important therapeutic option for this patient population.

Keywords

DasatinibChronic myeloid leukemiaAsianPharmacokineticsCytogenetic response

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Dong-Wook Kim
    • 1
  • Yeow-Tee Goh
    • 2
  • Hui-Hua Hsiao
    • 3
  • Priscilla B. Caguioa
    • 4
  • Dongho Kim
    • 1
  • Wan-Seok Kim
    • 1
  • Tapan Saikia
    • 5
    • 6
  • Shruti Agrawal
    • 7
  • Amit Roy
    • 7
  • David Dai
    • 7
  • M. Brigid Bradley-Garelik
    • 7
  • Jaydip Mukhopadhyay
    • 7
  • Saengsuree Jootar
    • 8
  1. 1.Division of Hematology, Seoul St. Mary’s HospitalThe Catholic University of KoreaSeoulKorea
  2. 2.Department of HematologySingapore General HospitalSingaporeSingapore
  3. 3.Division of Hematology, Kaohsiung Medical University HospitalKaohsiung Medical UniversityKaohsiungTaiwan
  4. 4.Faculty of Medicine and Surgery, St. Luke’s Medical CenterUniversity of St. TomasManilaPhilippines
  5. 5.Department of MedicinePrince Aly Khan HospitalMumbaiIndia
  6. 6.Department of MedicineJaslok HospitalMumbaiIndia
  7. 7.Bristol-Myers SquibbLawrencevilleUSA
  8. 8.Department of Medicine, Faculty of MedicineRamathibodi HospitalBangkokThailand